Modeling the cost-effectiveness of prolonged-release fampridine for the treatment of walking impairment in patients with multiple sclerosis in Sweden

Conclusions PR-fampridine represents a cost-effective treatment for MS-related walking impairment in Sweden, due to improvements in patients' quality of life and reduced healthcare resource utilization.PMID:33966549 | DOI:10.1080/13696998.2021.1927746

Source: Journal of Medical Economics - May 10, 2021 Category: Health Management Authors: C Acosta M Gianinazzi T Dort N Armstrong S Ryder T Lundqvist M Ekelund J Lycke Source Type: research